Live Breaking News & Updates on டாக்டர் ரந்தீப் குலேரியா|Page 5

Stay updated with breaking news from டாக்டர் ரந்தீப் குலேரியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Mission Vaccine: Controversy over 'Covishield' name; notice issued to SII


Adar Poonawala
India is all set to receive the 1st Covid-19 vaccine as the Drug Controller General of India (DCGI) on Sunday has approved Oxford AstraZeneca’s CoviShield and Bharat Biotech’s Covaxin for restricted use in India. India is gearing up to begin the biggest vaccination drive for one nation in history. However, controversy has arisen over the name of the Pune-based Serum Institue of India’s vaccine. A civil court in Pune issued a notice to SII on the application of a pharmaceutical company and vendor.
This vaccine, prepared by Oxford University, has been named ‘Covishield’ but at the same time, Adar Poonawala’s company has received notice regarding the name of the vaccine. The notice requested the Serum Institute of India to stop using ‘Covishield’ trademarks or other similar names in its upcoming covid-19 vaccination. This has been filed by Maharashtra’s Nanded-based firm, Cutis-Biotech claiming that they had been using the ‘Kovishield’ tr ....

Oxford Astrazeneca Covishield , Adar Poonawalla , Krishna Ella , Adar Poonawala , Oxford University , Serum Institute Of India , Drug Controller General , Oxford Astrazeneca , Bharat Biotech , Pune Based Serum Institue , Serum Institute , Bharat Biotech Chairman , Balram Bhargava , Drugs Controller General Of India , Corona Virus , Covid 19 , Covid Vaccine , Aiims Director , Dr Randeep Guleria , Indian Council Of Medical Research , Dr Krishna Ella , அடார் பூனாவல்ல , கிருஷ்ணா எல்லா , அடார் பூனாவள , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , சீரம் நிறுவனம் ஆஃப் இந்தியா ,

Mission Vaccine: From cost, doses to who pays, Dr Guleria lays blueprint for India's vaccine strategy


Dr Randeep Guleria
In a major development against Covid-19 pandemic in India, the Centre has approved Serum Institute’s Covishield for emergency authorisation in India. As the country awaits DCGI’s nod on the same, it is conducting one of the biggest vaccine dry runs today to ensure smooth planning and implementation of the immunisation programme. While there is still time for the immunisation process to begin, about 130 crore Indians have surely got their hopes high for a vaccine.
To answer some of the most asked questions about the immunisation programme, The Daily Guardian recently got in a conversation with AIIMS director Dr Randeep Guleria and here’s what he said. ....

Omega Covid , Randeep Guleria , Serum Institute Covishield , Serum Institute , Daily Guardian , Dr Randeep Guleria , Covid 19 Vaccine In India , India Covid Vaccine , Covid Vaccine Preparedness , The Daily Guardian , ரந்தீப் குலேரியா , சீரம் நிறுவனம் , தினசரி பாதுகாவலர் , டாக்டர் ரந்தீப் குலேரியா , தி தினசரி பாதுகாவலர் ,